



Dyve Biosciences to Present at the 2019 Annual ACR Meeting

Pilot Study Assessing the Efficacy and Safety of a Transdermally Delivered Sodium Bicarbonate and Menthol Lotion for Reducing the Pain Associated with Acute Gout Flares

October 22, 2019 – Thousand Oaks, California – Dyve Biosciences, a biotech drug delivery company that has developed a proprietary topical skin penetration technology that broadly enables needle-like drug delivery in a needleless topical, announced the presentation of a pilot study at the American College of Rheumatology (“ACR”) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia.

The ACR abstract is available online on the conference [website](#). Information from the ACR presentations are under embargo until November 9, 2019 at 4:30 p.m. ET. Once the posters are made public, they will be available on the Company’s website in the [Publications and Presentations section](#).

Presentation Details:

Abstract #1216: Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy And Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Flare

Session: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Presentation Time: Monday, November 11, 9:00 -11:00am (Hall B5)

Presenter: Smitha Reddy, MD, Director of the Arthritis Care and Research Center, San Diego, CA

About Dyve Biosciences

Dyve Biosciences is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary Dyve skin penetration technology. The innovative approach enables therapy to be transported from the surface of the skin into the blood with needle-like speed and pill-like efficiency. Dyve has advanced clinical programs in gout and melasma and a robust pre-clinical and clinical data set across multiple unique molecules. At Dyve, the focus is on robust science, compelling data, and delivering positive patient outcomes. For more information please visit www.dyvebio.com.

Contact

Audra Friis
audra@pascalecommunications.com
917.519.9577

###